China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) - Net Assets
Based on the latest financial reports, China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) has net assets worth CN¥37.38 Billion CNY (≈ $5.47 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥56.56 Billion ≈ $8.28 Billion USD) and total liabilities (CN¥19.18 Billion ≈ $2.81 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of China Resources Sanjiu Medical & Pharmac to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥37.38 Billion |
| % of Total Assets | 66.08% |
| Annual Growth Rate | 15.07% |
| 5-Year Change | 79.64% |
| 10-Year Change | 229.11% |
| Growth Volatility | 47.4 |
China Resources Sanjiu Medical & Pharmaceutical Co Ltd - Net Assets Trend (1997–2024)
This chart illustrates how China Resources Sanjiu Medical & Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 000999 total asset value for the complete picture of this company's asset base.
Annual Net Assets for China Resources Sanjiu Medical & Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual net assets of China Resources Sanjiu Medical & Pharmaceutical Co Ltd from 1997 to 2024. For live valuation and market cap data, see 000999 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥25.26 Billion ≈ $3.70 Billion |
+4.10% |
| 2023-12-31 | CN¥24.26 Billion ≈ $3.55 Billion |
+38.38% |
| 2022-12-31 | CN¥17.53 Billion ≈ $2.57 Billion |
+11.59% |
| 2021-12-31 | CN¥15.71 Billion ≈ $2.30 Billion |
+11.76% |
| 2020-12-31 | CN¥14.06 Billion ≈ $2.06 Billion |
+9.14% |
| 2019-12-31 | CN¥12.88 Billion ≈ $1.89 Billion |
+15.34% |
| 2018-12-31 | CN¥11.17 Billion ≈ $1.63 Billion |
+10.31% |
| 2017-12-31 | CN¥10.12 Billion ≈ $1.48 Billion |
+16.09% |
| 2016-12-31 | CN¥8.72 Billion ≈ $1.28 Billion |
+13.65% |
| 2015-12-31 | CN¥7.67 Billion ≈ $1.12 Billion |
+9.70% |
| 2014-12-31 | CN¥7.00 Billion ≈ $1.02 Billion |
+9.97% |
| 2013-12-31 | CN¥6.36 Billion ≈ $930.82 Million |
+14.08% |
| 2012-12-31 | CN¥5.58 Billion ≈ $815.96 Million |
+14.96% |
| 2011-12-31 | CN¥4.85 Billion ≈ $709.79 Million |
+8.67% |
| 2010-12-31 | CN¥4.46 Billion ≈ $653.19 Million |
+12.96% |
| 2009-12-31 | CN¥3.95 Billion ≈ $578.22 Million |
+15.79% |
| 2008-12-31 | CN¥3.41 Billion ≈ $499.38 Million |
+18.35% |
| 2007-12-31 | CN¥2.88 Billion ≈ $421.94 Million |
+13.29% |
| 2006-12-31 | CN¥2.55 Billion ≈ $372.44 Million |
+6.39% |
| 2005-12-31 | CN¥2.39 Billion ≈ $350.07 Million |
+4.57% |
| 2004-12-31 | CN¥2.29 Billion ≈ $334.78 Million |
-26.05% |
| 2003-12-31 | CN¥3.09 Billion ≈ $452.72 Million |
+6.61% |
| 2002-12-31 | CN¥2.90 Billion ≈ $424.65 Million |
-1.70% |
| 2001-12-31 | CN¥2.95 Billion ≈ $432.00 Million |
-0.94% |
| 2000-12-31 | CN¥2.98 Billion ≈ $436.10 Million |
+12.31% |
| 1999-12-31 | CN¥2.65 Billion ≈ $388.31 Million |
+255.19% |
| 1998-12-31 | CN¥747.10 Million ≈ $109.32 Million |
+30.92% |
| 1997-12-31 | CN¥570.67 Million ≈ $83.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to China Resources Sanjiu Medical & Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1612109317600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥16.12 Billion | 81.00% |
| Common Stock | CN¥1.28 Billion | 6.45% |
| Other Components | CN¥2.50 Billion | 12.55% |
| Total Equity | CN¥19.90 Billion | 100.00% |
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of China Resources Sanjiu Medical & Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hyosung Heavy Industries Corp
KO:298040
|
$6.31 Billion |
|
F.N.B. Corp
NYSE:FNB
|
$6.31 Billion |
|
Guanghui Energy Co Ltd
SHG:600256
|
$6.31 Billion |
|
Figure Technology Solutions, Inc. Class A Common Stock
NASDAQ:FIGR
|
$6.31 Billion |
|
Paycom Software, Inc.
NYSE:PAYC
|
$6.30 Billion |
|
Southwest Gas Holdings Inc
NYSE:SWX
|
$6.30 Billion |
|
Fertilizers and Chemicals Travancore Limited
NSE:FACT
|
$6.29 Billion |
|
ViaSat Inc
NASDAQ:VSAT
|
$6.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Resources Sanjiu Medical & Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,967,141,875 to 19,903,111,306, a change of 935,969,431 (4.9%).
- Net income of 3,367,888,969 contributed positively to equity growth.
- Dividend payments of 2,834,425,365 reduced retained earnings.
- Share repurchases of 2,208,928 reduced equity.
- Other factors increased equity by 404,714,755.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥3.37 Billion | +16.92% |
| Dividends Paid | CN¥2.83 Billion | -14.24% |
| Share Repurchases | CN¥2.21 Million | -0.01% |
| Other Changes | CN¥404.71 Million | +2.03% |
| Total Change | CN¥- | 4.93% |
Book Value vs Market Value Analysis
This analysis compares China Resources Sanjiu Medical & Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.67x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 63.52x to 1.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.41 | CN¥25.91 | x |
| 1998-12-31 | CN¥0.55 | CN¥25.91 | x |
| 1999-12-31 | CN¥2.02 | CN¥25.91 | x |
| 2000-12-31 | CN¥2.03 | CN¥25.91 | x |
| 2001-12-31 | CN¥2.05 | CN¥25.91 | x |
| 2002-12-31 | CN¥2.12 | CN¥25.91 | x |
| 2003-12-31 | CN¥2.29 | CN¥25.91 | x |
| 2004-12-31 | CN¥1.66 | CN¥25.91 | x |
| 2005-12-31 | CN¥1.75 | CN¥25.91 | x |
| 2006-12-31 | CN¥1.88 | CN¥25.91 | x |
| 2007-12-31 | CN¥2.08 | CN¥25.91 | x |
| 2008-12-31 | CN¥2.52 | CN¥25.91 | x |
| 2009-12-31 | CN¥2.88 | CN¥25.91 | x |
| 2010-12-31 | CN¥3.30 | CN¥25.91 | x |
| 2011-12-31 | CN¥3.59 | CN¥25.91 | x |
| 2012-12-31 | CN¥4.16 | CN¥25.91 | x |
| 2013-12-31 | CN¥4.82 | CN¥25.91 | x |
| 2014-12-31 | CN¥5.32 | CN¥25.91 | x |
| 2015-12-31 | CN¥5.97 | CN¥25.91 | x |
| 2016-12-31 | CN¥6.75 | CN¥25.91 | x |
| 2017-12-31 | CN¥7.73 | CN¥25.91 | x |
| 2018-12-31 | CN¥8.49 | CN¥25.91 | x |
| 2019-12-31 | CN¥9.87 | CN¥25.91 | x |
| 2020-12-31 | CN¥10.79 | CN¥25.91 | x |
| 2021-12-31 | CN¥12.01 | CN¥25.91 | x |
| 2022-12-31 | CN¥13.37 | CN¥25.91 | x |
| 2023-12-31 | CN¥14.83 | CN¥25.91 | x |
| 2024-12-31 | CN¥15.54 | CN¥25.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Resources Sanjiu Medical & Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.92%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.20%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 2.01x
- Recent ROE (16.92%) is above the historical average (11.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 19.03% | 8.90% | 0.76x | 2.83x | CN¥46.89 Million |
| 1998 | 21.71% | 10.58% | 0.84x | 2.46x | CN¥81.35 Million |
| 1999 | 8.55% | 14.92% | 0.41x | 1.39x | CN¥-37.37 Million |
| 2000 | 7.81% | 11.03% | 0.31x | 2.28x | CN¥-56.67 Million |
| 2001 | 4.65% | 6.48% | 0.28x | 2.53x | CN¥-139.36 Million |
| 2002 | 6.11% | 7.62% | 0.32x | 2.54x | CN¥-104.87 Million |
| 2003 | 7.18% | 7.81% | 0.32x | 2.85x | CN¥-82.14 Million |
| 2004 | -34.10% | -29.28% | 0.34x | 3.40x | CN¥-932.18 Million |
| 2005 | 5.37% | 4.04% | 0.42x | 3.15x | CN¥-103.34 Million |
| 2006 | 6.88% | 5.75% | 0.41x | 2.94x | CN¥-74.76 Million |
| 2007 | 10.25% | 8.23% | 0.44x | 2.85x | CN¥6.82 Million |
| 2008 | 15.63% | 11.59% | 0.85x | 1.58x | CN¥180.08 Million |
| 2009 | 19.25% | 14.62% | 0.86x | 1.53x | CN¥340.86 Million |
| 2010 | 19.37% | 18.69% | 0.72x | 1.45x | CN¥394.69 Million |
| 2011 | 16.73% | 13.76% | 0.73x | 1.67x | CN¥305.95 Million |
| 2012 | 19.23% | 14.71% | 0.81x | 1.62x | CN¥490.11 Million |
| 2013 | 18.03% | 15.20% | 0.71x | 1.67x | CN¥493.91 Million |
| 2014 | 15.32% | 14.24% | 0.68x | 1.58x | CN¥359.89 Million |
| 2015 | 16.50% | 15.81% | 0.66x | 1.59x | CN¥492.06 Million |
| 2016 | 13.90% | 13.34% | 0.66x | 1.57x | CN¥336.34 Million |
| 2017 | 13.23% | 11.71% | 0.69x | 1.65x | CN¥317.84 Million |
| 2018 | 13.23% | 10.67% | 0.74x | 1.67x | CN¥349.31 Million |
| 2019 | 16.71% | 14.19% | 0.74x | 1.60x | CN¥842.46 Million |
| 2020 | 11.64% | 11.71% | 0.62x | 1.60x | CN¥224.78 Million |
| 2021 | 13.45% | 13.22% | 0.64x | 1.59x | CN¥526.85 Million |
| 2022 | 14.40% | 13.54% | 0.67x | 1.59x | CN¥747.84 Million |
| 2023 | 15.04% | 11.53% | 0.62x | 2.12x | CN¥956.22 Million |
| 2024 | 16.92% | 12.20% | 0.69x | 2.01x | CN¥1.38 Billion |
Industry Comparison
This section compares China Resources Sanjiu Medical & Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,784,080,233
- Average return on equity (ROE) among peers: 10.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) | CN¥37.38 Billion | 19.03% | 0.51x | $6.31 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $52.15 Million | 21.80% | 0.58x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $24.03 Million | 18.61% | 1.45x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $19.92 Billion | 17.54% | 0.52x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.33 Billion | 7.89% | 0.52x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.54 Million | 1.60% | 1.47x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $870.26 Million | 1.00% | 1.90x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $10.66 Billion | 9.94% | 0.14x | $3.30 Billion |
About China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products,… Read more